New Amsterdam Pharma CO N.V. NAMS
We take great care to ensure that the data presented and summarized in this overview for NewAmsterdam Pharma Co N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NAMS
Top Purchases
Top Sells
About NAMS
Insider Transactions at NAMS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Michael H. Davidson Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+2.38%
|
$85,000
$17.26 P/Share
|
|
Mar 26
2024
|
James N Topper |
BUY
Open market or private purchase
|
Indirect |
8,429
+0.28%
|
$177,009
$21.5 P/Share
|
|
Mar 26
2024
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
190,476
-100.0%
|
$3,999,996
$21.5 P/Share
|
|
Mar 26
2024
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
11,197
-5.55%
|
$246,334
$22.72 P/Share
|
|
Mar 26
2024
|
Johannes Jacob Pieter Kastelein Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
201,673
+50.0%
|
-
|
|
Feb 13
2024
|
Louis G Lange |
BUY
Open market or private purchase
|
Indirect |
5,000
+16.73%
|
$95,000
$19.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
220K
Shares
From
4
Insiders
| Open market or private purchase | 18.4K shares |
|---|---|
| Exercise of conversion of derivative security | 202K shares |
Sell / Disposition
202K
Shares
From
2
Insiders
| Payment of exercise price or tax liability | 11.2K shares |
|---|---|
| Open market or private sale | 190K shares |